A newanalogue of vicenistatin was isolated from the producing strain Streptomyces sp. HC-34. A characteristic of the elucidated structure involved the existence of a neutral sugar mycaroseinstead of an aminosugar vicenisamine of vicenistatin. Theabsolute stereochemistry of the new analogue (named as vicenistatin M) was determined by the synthesis of D-mycarose and of vicenistatin Mitself. Biological testing of vicenistatin Msuggested the importance of vicenisamine for exerting the cytotoxicity of vicenistatin.
Vicenistatin
(1), an antitumor antibiotic isolated from
Streptomyces sp. HC-34, is unique in its structure including a 20-memberedmacrocyclic lactam aglycon and a novel aminosugar (vicenisamine).^The absolute stereochemistry of the aglycon was determined as shown in Fig. 1 .2) Its significant antitumor activity and unique structure prompted us to launch synthetic and biosynthetic studies for modification in order to clarify the essential chemical features for the biological activities.
The whole 20-membered macrolactam ring skeleton was successfully synthesized and the absolute configuration was verified. 3) In the course of the biosynthetic studies, the fermentation broth of Streptomyces sp. HC-34 was further analyzed more closely.
Continuous HPLC analysis with an aid of photodiode array (PDA) detection suggested the presence of an analogue of vicenistatin in a crude extract of the fermentation. Similarity of the aglycon structure to that of vicenistatin was easily predicted on the basis of the PDA absorption spectrum. This new metabolite was shown to be accumulated predominantly in the mycelium of the producing microorganism. Isolation and purification of this compound (2) was accomplished by solvent extraction of the filtered mass, followed by a series of chromatography as described in the experimental section.
The new compound 2 was characterized by physicochemical (Table 1 ) and spectroscopic methods. UVand IR spectra suggested close similarity of 2 to vicenistatin 1. The aglycon part was in fact determined to be totally identical with that of 1 by comparison of 1H-, 13C-NMR spectra including^H COSY,HMQC, the data being summarized in Table 2 . Significant difference was found in the sugar part; 1) a lack of the Af-methyl group of 1 (<5H 2.42ppm, singlet), 2) a lack of3' -H of 1 (5H 4.39ppm, ddd), 3) an appearance of a singlet methyl group (<5H 1.52ppm). The coupling constants (/H= 1.9, 9.6 Hz) between the anomeric proton (l'-H) and the adjacent methylene protons (2'-H) indicated the glycosidic linkage as /3. The odd molecular weight (MW501) deduced from FAB-MS (M+H+=m/z 502) spectra suggested the sugar moiety to be a neutral hexose rather than an aminohexose. The^-spin network indicated the sugar being either a mycarose (2,6-dideoxy-3- significant nuclear Overhauser effect between 4'-H and the 3'-methyl singlet, and the sugar was determined to be a mycarose (Fig. 2) . Accordingly, we designated this new analogue 2 as vicenistatin M. In fact, methyl /3-mycaroside was degradatively derived from 2, but only in a small amount. Unfortunately therefore, reliable optical rotation data was not obtained because of the lack of quantity. However, since vicenisamine, which is the original sugar component of 1, is known as D-sugar,1} we proposed that mycarose in 2 could also be the same D-configuration.
There are some precedence of mycarose found in antibiotics. L-Mycarose is commonly known in such antibiotics as magnamycin, erythromycin C and D, tylosin, and kedarcidin chromophore. D-Mycarose is rarely known, only found in mithramycin4) and P371 Al5). In order to unambiguously determine the absolute stereochemistry of 2, synthetic approach was undertaken to D-mycarose and 2 itself.
As mentioned above, the aglycon of 1 and 2 is identical.
It was also established already that the macrolactam aglycon could be obtained from natural vicenistatin 1. Therefore, what we had to do here was the synthesis of dmycarose and its glycosidation with the macrolactam.
The synthetic route for D-mycarose, being shown in Scheme 1, was mainly adopted from the Flaherty's6) and The next stage of our work was glycosidation. It should be noted that, once it finely crystallizes, the free aglycon of I is extremely insoluble in any solvents. Therefore, it is necessary to suitably protect the 7-OH group of the aglycon, which should be directly used for glycosidation. The 0-TMS (trimethylsilyl) ether was ultimately selected as a glycosyl acceptor, which was in fact obtained in good yield by methanolysis of natural 1, followed by the standard TMSprotection. Naturally, 1-O-acetyl sugar was chosen as a glycosyl donor, because of its ease of preparation and its usefulness in glycosidation with O-TMS-alcohol.10) At first, both of the hydroxy groups of methyl a-D-mycaroside 7 were protected as a cyclic carbonate with N, TV'-carbonyl- b coupling constants (7, Hz).
c obscured by overlapping.
mixture was subsequently deprotected by hydrolysis to give /J-glycoside (l' -H: dd, 7= 1.9, 9.5 Hz) and a-glycoside (I' -ll: d, 7=3.8 Hz), which were ultimately separated by flash silica gel chromatography.
Unfortunately, the desired /3-glycoside was a minor product (/3: a=28:72), but the spectroscopic properties of the obtained /3-glycoside were completely identical with those of natural 2 ( Fig. 3 ). In conclusion, the absolute stereochemistry of the sugar part in vicenistatin Mwas determined to be D-mycarose.
Since the sugar moiety of 2 was determined to be different from 1, we anticipated that biological comparison between them could shed light oft the role of the sugar moiety of this class of antibiotics.
Vicenistatin M(2) was subjected to the bioassay for in vitro cytotoxicity, but essentially no activity was observed against several cell lines including humanlung carcinoma: 
Isolation and Purification
The fermentation was conducted under the same conditions as previously published.1} Fermentation broth (4.5 liters) was centrifuged and the resulting mycelium cake (wet weight, 253g) was allowed to stand overnight in acetone (1 liter) for extraction. The whole was filtered and the acetone extract was concentrated in vacuo to give an aqueous solution. This solution was adjusted to pH10 and further extracted with EtOAc (1.2liters). The organic extract was evaporated and the residue was chromatographed over silica gel with CHCl3/MeOH (100 : 1 to 5 : 1). The appropriate fractions were combined and further Scheme 1. Synthesis ofD-mycarose.
* Based on the suggestion of a referee, we synthesized a /3-L-mycarosyl analog of vicenistatin M. Protected L-mycarose, which was degradatively derived from commercially available tylosin tartrate, was reacted with the O-TMSether of the aglycon in a similar mannar to give the desired analog and its^-NMRspectral data were clearly different from those of natural vicenistatin M. !H-NMRspectral data of the /3-L-mycarosyl analog (pyridirie-</5); S 0. Methyl 2,6-Dideoxy-3-C-methyla-D-n6o-hexopyranoside (methyl g-p-mycaroside)
To an ice-cooled solution of6 (3.59g, 10.0mmol) in dry tetrahydrofuran (80ml) was added lithium aluminum hydride (1.52g, 40.0mmol). After being refluxed for 2.5 hours, the reaction mixture was ice-cooled, to which were added dropwise water (1.52ml), 15% NaHCO3 aq. (1.52 ml), and water (4.56ml) successively, and the whole was then stirred at roomtemperature for 0.5 hour. Celite and Methyl 3 ,4-0-Carbonyl-2,6-dideoxy-3 -C-methyl-a-D-n&o-hexopyranoside (8) To a solution of 7 (845mg, 4.79mmol) in dry benzene (39ml) was added AyV' -carbonyldiimidazole (3.1 1 g, 19.2 mmol) and the reaction mixture was stirred at 50°C for 30 minutes. After cooling, water was added to the solution and the mixture was extracted with EtOAc (50mix3). The combined extract was dried (MgSO4), and concentrated in A solution of 8 (547mg, 2.72mmol) in AcOH (30ml) and water (6ml) was heated at around 90°C for 21 hours.
The reaction mixture was evaporated in vacuo with an aid of azeotropic distillation with toluene. The residue was purified by column chromatography (silica gel, 50g; hexane/EtOAc, 5: 1 to 1 : 1) to afford 400mg of 9 (yield 78%); mp 108. To a solution of 9 (95mg, 0.51mmol) in pyridine (0.3 ml) was added Ac2O (53 /il, 0.56mmol) and the mixture was stirred at room temperature, for 3.5 hours. The reaction wasquenched by the addition of water and the mixture was extracted with EtOAc (30mix3). The combined extract was dried (MgSO4), and concentrated in vacuo. To a HCl-MeOH solution, which had been prepared by adding AcCl (9.00ml, 127mmol) to an ice-cooled MeOH (160ml), was added natural vicenistatin 1 (776mg, mmol) at roomtemperature and the reaction mixture was stirred at room temperature for 23 hours. After the addition of Et3N (19.0ml, 136mmol) at 0°C, the mixture was concentrated in vacuo. To an ice-cooled suspension of the residue, Et3N (10.0ml, 71.7mmol) and DMAP (216mg, 1.77mmol) in dry CH2C12 (160ml) was added. TMSC1 (5.0ml, 39mmol) was further added and the reaction mixture was stirred for 1 hour. To the resulting clear solution was added crushed ice and water, and the mixture was extracted with Et2O (100 mix3). The extract was washed with water (50ml) and brine (50 ml) successively, and was then dried (MgSO4) and concentrated in vacuo. The residue was purified by flash column chromatography (silica gel, 80 g; hexane/EtOAc, 
